tbuckley/cabot-search huggingface dataset:
My Stethoscope
Authors: George A Sarosi
Journal: Annals of Internal Medicine (2012)

On Being a Doctor3 January 2012My StethoscopeGeorge A. Sarosi, MDGeorge A. Sarosi, MDFrom Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-1-201201030-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail As I dug through the drawers of a forgotten cabinet, I found my old slide rule. Forty-five years ago, this instrument had been critical to my daily life and dangled from my belt for at least 2 years. It saw steady, daily use, and with it, I was able to do complex calculations effortlessly. I immediately tried to use it, and to my chagrin, I found I could not. Even after searching online for operating instructions, I found it all but impossible.Directly under this archeological stratum that had preserved the slide rule was my old, broken stethoscope—an original Leatham ... Author, Article, and Disclosure InformationAffiliations: From Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417.Corresponding Author: George A. Sarosi, MD, Minneapolis Veterans Affairs Medical Center, One Veterans Drive, Minneapolis, MN 55417; e-mail, george.[email protected]gov. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 January 2012Volume 156, Issue 1_Part_1Page: 62-63KeywordsAuscultationCardiovascular therapyEchocardiographyEjection fractionHeartHeart failureIntensive care unitsPatientsStenosisThorax ePublished: 3 January 2012 Issue Published: 3 January 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Proprioception in Extraocular Muscle
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal of Pharmacy and Pharmacology, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Childhood sacrococcygeal epidermoid cyst
Authors: A. S. Patchefsky
Journal: JAMA (1970)

<h3>To the Editor.—</h3> A defect during the complex embryological development of the sacrococcygeal area may give rise to a wide variety of lesions. The lesions presenting in the pediatric age group include benign and malignant teratomas, duplication cysts, anterior myelomeningoceles, neurogenic tumors, and, rarely, chordomas.<sup>1</sup>Sacrococcygeal epidermoid cysts have been reported mainly in the female adult and are uncommonly encountered in pediatric practice.<sup>2,3</sup>A 4-year-old male child with a precoccygeal epidermoid cyst is the subject of this case report. <h3>Report of a Case.—</h3> A 4-year-old Negro boy was admitted on Feb 16, 1969. to the pediatric surgical service of the Jefferson Medical College Hospital because of a posterior rectal mass. Six days before, during evaluation for nausea, vomiting, and abdominal pain, the mass was palpateld on rectal examination. The child's symptoms regressed spontaneously after 24 hours, and he remained asymptomatic until admission. A history of intermittent constipation since
Helicobacter pylori testing is useful only in high risk patients
Journal: BMJ (2001)

Helicobacter pylori testing is useful only in high risk patientsHelicobacter pylori testing in primary care is useful only in those at higher risk of developing peptic ulcer disease and is of no value in those at lower risk Three simple points from a patient's history-smoking, pain on an empty stomach, and history of peptic ulcer disease-can distinguish between those at high risk and those at low risk of peptic ulcer disease.In their cross sectional study of 565 primary care patients in the Netherlands, Weijnen and colleagues (p 71) found that these three variables had odds ratios of 5.5, 2.8, and 2.0 respectively.In those found to be at higher risk using this scoring rule, the predictive value for the presence of peptic ulcer disease increased from 16% to 26% after a positive Helicobacter pylori test.
AMERICAN ROENTGEN RAY SOCIETY
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PSYCHOLOGY OF CHESS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vector-electrocardiographic exercise test in ischemic heart disease. A more objective measure of exercise tolerance
Authors: J. H. Isaacs
Journal: JAMA (1966)

Exercise tolerance was measured in 59 subjects with functional class 2, 3, and 3-4 ischemic heart disease with a standardized treadmill exercise, the end point of which was the appearance of an ischemic ST segment, an ischemic T loop, angina, or disabling dyspnea or fatigue. Forty-seven (80%) exhibited an ischemic T loop, but only 35 (60%) exhibited an ischemic ST segment during or after exercise. Twelve of the 59 (20%), therefore, exhibited an ischemic T loop unassociated with an ischemic ST segment. Results were reproducible despite the many variables that influence the course of ischemic heart disease. These results indicate that the duration of this exercise to the appearance of electrocardiographic or vectorcardiographic changes of ischemia represents a practical and objective measure of exercise tolerance in ischemic heart disease.
"LOIMOGRAPHIA," A DESCRIPTION OF THE GREAT PLAGUE.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sunset
Authors: Asiri Ediriwickrema
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A single-arm, open-label, multi-center study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Authors: I. W. Flinn, S. Goldberg, R. L. Robles, D. Rizzieri, J. P. Radich, M. J. Mauro, S. Ericson, J. E. Cortes
Journal: Journal of Clinical Oncology (2011)

TPS204 Background: With more potent tyrosine kinase inhibitors, increasingly sensitive methods are required to monitor treatment response and quantify minimal residual disease (MRD). Molecular monitoring is recommended by National Comprehensive Cancer Network and European LeukemiaNet guidelines; major molecular response (MMR) correlates with optimal long-term outcomes. CMR, while implying absence of Bcr-Abl transcripts, is defined by levels undetectable by current technology (generally accepted to be < 4 or 4.5 logs reduced below a standardized baseline using quantitative real-time polymerase chain reaction [RT-PCR]). Newer technologies that can detect larger reductions will be important in analyzing correlations between decreased disease burden and long-term outcomes, and may assist in selecting patients for “stopping” therapy. Methods: This multi-center US study plans to enroll 300 adults with Ph+ CML-CP within 3 months of diagnosis to receive nilotinib 300 mg twice daily (BID) for up to 4 years. BCR-ABL transcripts are quantified using RT-PCR at a central laboratory. An exploratory molecular assay with an additional >1-log sensitivity and mutation detection and quantification will be evaluated. The primary endpoint is the rate of confirmed CMR (by second PCR sample within 3 months; ≥4.5-log reduction of BCR-ABL from standardized baseline on the international scale [IS], equivalent to BCR-ABL ≤0.0032% IS) at 24 months. Dose escalation to 400 mg BID is allowed for patients not in CMR at 2 years. Secondary endpoints include rate of, time to, and duration of complete cytogenetic (CCyR), MMR, CMR, and sustained (2-year) CMR; rate and time to loss of CCyR, MMR, CMR, sustained CMR and to progression to accelerated phase/blast crisis; rate of CMR in dose-escalated patients; event-free, progression-free, and overall survival; BCR-ABL trends and correlation of mutations with response (exploratory). The exploratory molecular assay data will provide information on BCR-ABL trends below the current CMR threshold and assist in evaluating lower levels of MRD and the potential for cure.
Industrial Diseases.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts
Journal: Annals of the Rheumatic Diseases (1955)

Steroids; Other General Subjects.At the end of each section is a list of titles of articles noted but not abstracted.Not all sections may be represented in any one issue.The section "ACTH, Cortisone, and other Steroids" includes abstracts and titles of articles dealing with steroid research which, although not directly concerned with the rheumatic diseases, may make an important contribution to knowledge of the scope and modus operandi of steroid therapy.
Strange bedfellows: death penalty and medicine
Authors: B. Bolsen
Journal: JAMA (1982)

A group of Boston physicians are calling on their colleagues across the country to join them in opposing the death penalty as the wrong solution to a complex problem. "The medical profession does not keep itself away from social problems like the plague or typhoid," said psychiatrist Michael Nelson, MD. He urged physicians to consider criminal homicide and capital punishment as sociomedical issues that "deserve the best medical thinking." Nelson, who helped organize Massachusetts Physicians Against the Death Penalty in February and who would like to take it nationwide, spoke at a symposium on physicians and the death penalty held in conjunction with the Harvard Medical School commencement in June. Physician concern about the death penalty was triggered in 1977 when Oklahoma and Texas adopted a new "medical" method of execution—death by lethal injection. Idaho and New Mexico soon followed suit, and in Washington, the condemned may choose between lethal
V. THE USE OF ANTITOXIN IN THE TREATMENT OF DIPHTHERIA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Red Cross Reports Show That 117 Died Last Fall in Hurricane Sandy
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P72: Alitretinoin for chronic hand eczema in two dermatology centres: assessing real‐world use and predictors of response
Authors: J Hansen, E Didriksen Apol, M Sheikh, K Vadstrup, A Martin-Clavijo
Journal: British Journal of Dermatology (2021)

Real-world evidence on the therapeutic success of biologics in psoriasis can support clinical decision-making.Evidence on patient characteristics and the therapeutic success of brodalumab in everyday clinical practice is currently limited.The objective of the present study was to describe the demographics, disease severity and comorbidities, and to estimate drug survival, of patients with psoriasis treated with brodalumab included in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).This analysis included patients initiated on brodalumab in BADBIR from 19 January 2018 to 30 October 2020.Drug survival analysis was conducted by Kaplan-Meier estimation.Windowing analyses of Psoriasis Area and Severity Index (PASI), Physician's Global Assessment and Dermatology Life Quality Index (DLQI) for baseline and 12 months after the start of treatment was conducted as observed.In total, 213 adult patients receiving treatment with brodalumab for moderate-to-severe plaque psoriasis were included in this analysis.Patients were predominantly male (59Á2%), mean age was 23Á5 years, mean body mass index (BMI) was 33Á0, and mean baseline PASI and DLQI were 13Á0 (n = 127) and 16Á5 (n = 76), respectively.In total, 157 patients (73Á7%) had at least one comorbidity, the most common being hypertension (27Á2%), depression (26Á3%), diabetes (11Á7%) and psoriatic arthropathy (PsA; 6Á1%).Fifty patients (23Á5%) were biologic-na€ ıve, 101 (47Á4%) started brodalumab without a specified previous biologic and 62 (29Á1%) were biologic-experienced with a known previous biologic.The predicted drug survival probability at 12 months for all patients was 85Á2% [95% confidence interval (CI) 79Á6-91Á1].At 12 months, biologic-na€ ıve patients and patients with previous biologic use had similar drug survival [86Á2% (95% CI 75Á3-98Á6) and 85Á0% (95% CI 78Á8-91Á7), respectively]; elderly patients (those aged ≥ 65 years) had lower drug survival (79Á5%, 95% CI 59Á3-100) than those aged < 65 years (85Á6%, 95% CI 79Á9-91Á8); patients with a BMI < 30 and ≥ 30 at baseline had similar drug survival [85Á2% (95% CI 76Á0-95Á5) and 84Á2% (95% CI 77Á1-91Á9), respectively].PsA did not seem to affect drug survival [PsA: 83Á8% (95% CI 70Á2-100Á0); no PsA: 85Á3% (95% CI 79Á3-91Á8)].Thirty patients (14Á1%) stopped owing to lack of efficacy or adverse events (n = 13).At 12 months, 54 patients reported an absolute PASI score ≤ 2, and 33 an DLQI score of 0 or 1.This analysis indicates high and sustained drug survival rates for brodalumab after 1 year of treatment, irrespective of patient subgroup, as well as high rates of clearance in a real-world clinical setting.Further real-world